{
  "actions": [
    {
      "acted_at": "2010-03-02",
      "action_code": "Intro-H",
      "references": [],
      "text": "Introduced in House",
      "type": "action"
    },
    {
      "acted_at": "2010-03-02",
      "action_code": "H11100",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Referred to House Energy and Commerce",
      "type": "referral"
    },
    {
      "acted_at": "2010-03-02",
      "action_code": "H11100-A",
      "references": [],
      "text": "Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.",
      "type": "referral"
    },
    {
      "acted_at": "2010-03-02",
      "action_code": "H11100",
      "committees": [
        "HSWM"
      ],
      "references": [],
      "text": "Referred to House Ways and Means",
      "type": "referral"
    },
    {
      "acted_at": "2010-03-08",
      "action_code": "",
      "committees": [
        "HSWM"
      ],
      "references": [],
      "text": "Referred to the Subcommittee on Health.",
      "type": "referral"
    }
  ],
  "amendments": [],
  "bill_id": "hr4732-111",
  "bill_type": "hr",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "referral"
      ],
      "committee": "House Ways and Means",
      "committee_id": "HSWM"
    },
    {
      "activity": [
        "referral"
      ],
      "committee": "House Ways and Means",
      "committee_id": "HSWM",
      "subcommittee": "Subcommittee on Health",
      "subcommittee_id": "02"
    },
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF"
    }
  ],
  "congress": "111",
  "cosponsors": [
    {
      "bioguide_id": "B001149",
      "district": "5",
      "name": "Burton, Dan",
      "original_cosponsor": false,
      "sponsored_at": "2010-03-12",
      "state": "IN",
      "title": "Rep.",
      "withdrawn_at": null
    },
    {
      "bioguide_id": "C001078",
      "district": "11",
      "name": "Connolly, Gerald E.",
      "original_cosponsor": false,
      "sponsored_at": "2010-09-14",
      "state": "VA",
      "title": "Rep.",
      "withdrawn_at": null
    },
    {
      "bioguide_id": "F000030",
      "district": "17",
      "name": "Farr, Sam",
      "original_cosponsor": false,
      "sponsored_at": "2010-03-25",
      "state": "CA",
      "title": "Rep.",
      "withdrawn_at": null
    },
    {
      "bioguide_id": "H001039",
      "district": "19",
      "name": "Hall, John J.",
      "original_cosponsor": false,
      "sponsored_at": "2010-04-13",
      "state": "NY",
      "title": "Rep.",
      "withdrawn_at": null
    },
    {
      "bioguide_id": "L000111",
      "district": "4",
      "name": "Latham, Tom",
      "original_cosponsor": false,
      "sponsored_at": "2010-03-16",
      "state": "IA",
      "title": "Rep.",
      "withdrawn_at": null
    },
    {
      "bioguide_id": "M001137",
      "district": "6",
      "name": "Meeks, Gregory W.",
      "original_cosponsor": false,
      "sponsored_at": "2010-03-17",
      "state": "NY",
      "title": "Rep.",
      "withdrawn_at": null
    },
    {
      "bioguide_id": "R000409",
      "district": "46",
      "name": "Rohrabacher, Dana",
      "original_cosponsor": false,
      "sponsored_at": "2010-05-19",
      "state": "CA",
      "title": "Rep.",
      "withdrawn_at": null
    }
  ],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2010-03-02",
  "number": "4732",
  "official_title": "To amend the Federal Food, Drug, and Cosmetic Act to create a new conditional approval system for drugs, biological products, and devices that is responsive to the needs of seriously ill patients, and for other purposes.",
  "popular_title": null,
  "related_bills": [],
  "short_title": "Compassionate Access Act of 2010",
  "sponsor": {
    "bioguide_id": "W000794",
    "district": "33",
    "name": "Watson, Diane E.",
    "state": "CA",
    "title": "Rep.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2010-03-02",
  "subjects": [
    "Administrative remedies",
    "Advisory bodies",
    "Department of Health and Human Services",
    "Drug safety, medical device, and laboratory regulation",
    "Food and Drug Administration (FDA)",
    "Health",
    "Health care coverage and access",
    "Medical research",
    "Medicare"
  ],
  "subjects_top_term": "Health",
  "summary": {
    "as": "Introduced in House",
    "asOf": "2010-03-02",
    "date": "2010-05-13T19:44:34Z",
    "text": "Compassionate Access Act of 2010 - Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary of Health and Human Services (HHS) to permit an investigational drug, biological product, or device to be made available for expanded access under a treatment investigational new drug application or treatment investigational device exemption if specified Compassionate Investigational Access requirements are met.\n\nGives immunity to the manufacturer, distributor, administrator, sponsor, or physician from suit or liability relating to products approved under this Act.\n\nEstablishes a procedure for accelerated approval of an investigational drug, biological product, or device that is reasonably likely to predict clinical benefit to a patient suffering from a serious or life-threatening condition.\n\nRequires the Secretary to establish: (1) the Accelerated Approval Advisory Committee; (2) a new program to expand access to investigational treatments for individuals with serious or life threatening conditions and diseases; and (3) a demonstration project under the Medicare program to pay for drugs, biological, products, and devices approved under this Act.\n\nRequires the Secretary to consider the clinical judgment and risks to the patient from the disease or condition in evaluating the safety and effectiveness of drugs, biological products, and devices that treat serious or life-threatening diseases or conditions, including the evaluation of nonstatistical information.\n\nRequires any committee evaluating investigational drugs, devices, or biological product applications to have at least two patient representatives as voting members."
  },
  "titles": [
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Compassionate Access Act of 2010",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To amend the Federal Food, Drug, and Cosmetic Act to create a new conditional approval system for drugs, biological products, and devices that is responsive to the needs of seriously ill patients, and for other purposes.",
      "type": "official"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Compassionate Access Act of 2010",
      "type": "short"
    }
  ],
  "updated_at": "2023-01-11T13:16:27Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/111/hr/BILLSTATUS-111hr4732.xml"
}